Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
Hematology Disease Topics & Pathways:
Research, Translational Research
First, we evaluated the effects of H3B-8800 (H3B; an orally bioavailable small molecule inhibitor for SF3B complex) and PARPi (Olaparib or Talazoparib) in primary murine CM-AML cells. Compared to normal bone marrow (BM) cells, CM-AML cells showed significantly increased sensitivity to H3B (IC50: 55.21 ± 9.585 vs. 432.0 ± 21.49 nM; p<0.0001) and Olaparib (IC50: 4.394 ± 1.008 vs. 57.67 ± 2.358 µM; p<0.0001). Similar results were obtained in primary human inv(16) AML samples. Compared to HL-CD34+, inv(16)-CD34+ cells were significantly more sensitive to H3B (IC50: 40.45 ± 12.54 vs. 270.7 ± 18.04 nM; p<0.0001), Olaparib (IC50: 3.251 ± 1.498 vs. 28.04 ± 4.827 µM; p=0.0004) and Talazoparib (IC50: 130.4 ± 27.57 vs. 2681 ± 487.9 nM; p<0.0001). To test in vivo effects, cohorts of CM-AML mice were generated and given H3B (8 mg/kg), Talazoparib (0.25 mg/kg), or vehicle (0.5% methylcellulose) by daily oral gavage for 10 days. Compared with vehicle, H3B or Talazoparib group showed significantly reduced splenic disease burden (H3B: 0.253 ± 0.0214 g vs. 0.422 ± 0.0734 g; p=0.0401; Tala: 0.143 ± 0.033 g vs. 0.422 ± 0.0734 g; p=0.0051), decreased ckit+ blasts in BM (H3B: 7.825 ± 2.08% vs. 32.22 ± 2.689%; p<0.0001; Tala: 18.5 ± 2.422% vs. 32.22 ± 2.689%; p=0.0042), decreased ckit+ blasts in spleen (H3B: 9.4 ± 1.118% vs. 52.84 ± 5.326%; p<0.0001; Tala: 24.09 ± 6.973% vs. 52.84 ± 5.326%; p=0.0115) with prolonged survival (H3B: 95 vs. 68 days; p=0.0003; Tala: 95.5 vs. 68 days; p=0.0007).
In support of our hypothesis, analysis of Beat AML dataset showed that Olaparib-sensitive patients (IC50<4 μM) are enriched for HDAC8-high (top 50%) expression. In addition, HDAC8 overexpression (HDAC8-OE) in several cell lines representing different disease subtypes (MV4-11, HEL, MDS-L) were more sensitive to H3B, Olaparib, and Talazoparib compared to empty vector (EV) control. To assess in vivo effects, MV4-11-luciferase cells transduced with EV or HDAC8-OE vector were transplanted into NSGS mice (i.v. 0.5x106 cells/mouse, no radiation) and given H3B (8 mg/kg), Talazoparib (0.25 mg/kg), or vehicle (0.5% methylcellulose) by daily oral gavage for 10 days. Bioluminescence imaging showed a significant reduction in tumor burden in both H3B and Talazoparib treated groups compared to vehicle. MV4-11-Luci-HDAC8 cells were selectively more sensitive to H3B (HDAC8 vs. EV; p<0.0001) or Talazoparib (HDAC8 vs. EV; p=0.001) treatment with reduced tumor burden compared to MV4-11-Luci-EV cells. Compared to MV4-11-Luci-EV mice, significantly prolonged survival was seen for MV4-11-Luci-HDAC8 mice treated with H3B (HDAC8: 39 vs. EV: 31 days; p=0.0001) or Talazoparib (HDAC8: 36 vs. EV: 29 days; p=0.0002). Overall, these results indicate that both splicing modulator and PARPi can effectively target HDAC8-high AML cells, including inv(16) AML, offering novel therapeutic avenues for inv(16) AML and AML with aberrant high-HDAC8 activity.
Disclosures: Hua: GenomeFrontier Therapeutics: Current Employment.
See more of: Oral and Poster Abstracts